MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN), a biotech company specializing in the treatment of inner ear diseases, today announces that it has obtained Investigational New Drug (IND) status from the FDA for SENS-111, enabling the Company to initiate a clinical study in acute severe vertigo.
The FDA’s approval validates the preclinical and clinical trials led by Sensorion within the framework of its SENS-111 program, and notably the results obtained from 100 healthy volunteers in a phase 1b clinical trial. The latter helped confirm the compound’s safety and pharmacokinetic profile and provided guidance regarding the caloric test’s use within this population.
All the results of the phase 1b trial will be presented at two upcoming annual scientific conferences:
The American Academy of Otolaryngology-Head and Neck Surgery
Foundation (AAO-HNSF), September 18-21, 2016, in San Diego, California
Poster: SENS-111, H4 Antagonist for Treatment of Peripheral Vertigo, Is Safe
The European Association for Clinical Pharmacology and Therapeutics
(EACPT), October 6-9, 2016, in Opatija, Croatia
Oral presentation: The effect of SENS-111, a new H4R antagonist, on vertigo induced by caloric test in healthy volunteers is related to plasma concentrations
The aim of the phase 2 study, which is expected to begin during the second half of 2016, will be to prove SENS-111’s efficacy in treating the symptoms in patients with acute severe vertigo. The international study will notably be undertaken in the United States and Europe.
Pierre Attali, Sensorion’s Chief Medical Officer, comments: “The FDA’s approval to begin our first phase 2 clinical trial of SENS-111 is a major strategic milestone for Sensorion. It reflects a real need for easy-to-administer drugs to treat vertigo crisis and confirms Sensorion’s ability to rapidly take its R&D programs to the clinical stage. Our technological platform, which is capable of identifying molecules of therapeutic interest for inner ear disorders, active through systemic administration, plays a pivotal role in this process. Given the results demonstrated by SENS-111 in preclinical trials and the phase 1b study, we are confident in the success of this new study, which we expect to initiate during the second half of this year.”
There is currently a clear unmet medical need for new effective and well-tolerated treatments to alleviate the symptoms of vertigo crises that effect some 82 million patients worldwide1.
SENS-111 is the first representative of the histamine type 4 receptor antagonist class tested in inner-ear pathologies. This drug candidate displays a neuromodulation effect of the neurosensorial inner ear cell function and is being developed for the symptomatic treatment of vertigo crises or tinnitus. SENS-111 is a small molecule that can be taken orally or via a standard injection, and has been successfully assessed in humans in phase 1b.
Sensorion specializes in the treatment of pathologies of the inner ear such as acute vertigo, tinnitus and hearing loss. The company was founded by Inserm (the French Institute of Health and Medical Research) and is utilizing its pharmaceutical R&D experience and comprehensive technology platform to develop first-in-class easy-to-administer, notably orally active, drug candidate programs for treating hearing loss and the symptoms of vertigo and tinnitus, for preventing and treating complications associated with progressive lesions in the inner ear, and for preventing the toxicity of chemotherapy in the inner ear. Based in Montpellier, southern France, Sensorion received financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative.
Sensorion is listed on Alternext Paris since April 2015. www.sensorion-pharma.com
- Participation in the Rodman & Renshaw global investment conference, on September 11-13, 2016 (New York, USA)
- Participation in the Sachs Biotech Forum, on September 27-28, 2016 (Basel, Switzerland)
- Participation in the Midcap Event conference, on October 5-6, 2016 (Paris, France)
- Publication of 2016 first-half results, on October 31, 2016 (after market)
- Participation in the BIO Europe conference, on November 7-9, 2016 (Cologne, Germany)
- Participation in the Actionaria trade fair, on November 18-19, 2016 (Paris, France)
This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward-looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the prospectus on which the French Financial Market Authority (AMF) granted its visa n° 15-114 on March 27, 2015 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
1 Source: Alcimed, Sensorion
ISIN code: FR0012596468